Indaptus Therapeutics (INDP) Stock: Buy, Sell, or Hold?
INDP - Indaptus Therapeutics, Inc. Common Stock
$2.77
0.21 (8.20%)
▲
5d:
+138.79%
30d:
+171.57%
90d:
-22.41%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When INDP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: INDP is 58.3% above its trading range ($1.75). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: INDP is 58.3% above its trading range ($1.75). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: INDP is currently trading at $2.77, which is considered extended relative to its 30-day fair value range of $0.89 to $1.75.
Technical Outlook: Technically, INDP is in a downtrend. Immediate support is located at $1.09, while resistance sits at $2.94. The stock is showing strong short-term momentum, up 8.2% recently.
Market Sentiment: INDP scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+261.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INDP is in a downtrend. Immediate support is located at $1.09, while resistance sits at $2.94. The stock is showing strong short-term momentum, up 8.2% recently.
Market Sentiment: INDP scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+261.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.89 -
$1.75
Company Quality Score
37/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
15.8%
All Signals
- BEARISH: Price significantly overextended (+58.3% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: Strong upward momentum (+8.2%)
- BULLISH: Trading 261.0% below Wall St target ($10.00)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.89 -
$1.75
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.09
Resistance Level
$2.94
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.62
Wall Street Target
$10.00
(+261.0%)
Share & Embed Analysis
Last updated: September 13, 2026 5:10 AM ET
Data refreshes hourly during market hours. Next update: 6:10 AM
Data refreshes hourly during market hours. Next update: 6:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INDP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 44 HOLD |
